Digest Network Come funziona
Network
/
Società
En
Non verificato

Endeavor BioMedicines

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

12 comunicati stampa

Guarda tutti i comunicati
08/10/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
08/09/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Endeavor BioMedicines Presents New Quantitative Imaging Data from Analysis of Phase 2a Clinical Trial Evaluating Taladegib (ENV-101) in Patients with Idiopathic Pulmonary Fibrosis
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
25/08/2026
Industria
Eventi
Biotecnologia
Sanità
Salute
Medicina - Varie
Endeavor BioMedicines to Present Quantitative Image Analysis from Phase 2a Trial of Taladegib (ENV-101) at European Respiratory Society (ERS) Congress 2026
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
03/11/2025
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Endeavor BioMedicines Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
30/09/2025
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
10/09/2025
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
16/07/2025
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
20/05/2025
Industria
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
01/05/2025
Eventi
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0
02/04/2025
Mercato del lavoro
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Endeavor BioMedicines Appoints Internationally Renowned ILD Expert Lisa Lancaster, M.D., as Chief Medical Officer
Fonte
Endeavor BioMedicines
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0